Advertisement
Advertisement
FATE
Fate Therapeutics, Inc.
1.19
USDSponsored
+0.04
+3.04%
Apr 08, 10:11 UTC -4
Open
FATE Earnings Reports
Positive Surprise Ratio
FATE beat 23 of 41 last estimates.
56%
Next Report
Date of Next Report
May 11, 2026
Estimate for Q1 26 (Revenue/ EPS)
$1.08M
/-$0.28
Implied change from Q4 25 (Revenue/ EPS)
-20.93%
/+3.70%
Implied change from Q1 25 (Revenue/ EPS)
-33.55%
/-12.50%
Fate Therapeutics, Inc. earnings per share and revenue
On Feb 26, 2026, FATE reported earnings of -0.27 USD per share (EPS) for Q4 25, beating the estimate of -0.27 USD, resulting in a 1.85% surprise. Revenue reached 1.37 million, compared to an expected 1.34 million, with a 1.85% difference. The market reacted with a +5.41% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 13 analysts forecast an EPS of -0.28 USD, with revenue projected to reach 1.08 million USD, implying an increase of 3.70% EPS, and decrease of -20.93% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Palvella Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.92
Actual
-$1.07
Surprise
-15.20%
Pharvaris N.V. Ordinary Shares
Report Date
Apr 02, 2026 For Q4 25
Estimate
-$0.63
Actual
-$0.72
Surprise
-13.69%
Nanobiotix S.A. - ADR
Report Date
Mar 31, 2026 For Q4 25
Estimate
$0.55
Actual
-$0.39
Surprise
-170.16%
Innate Pharma S.A. ADS
Report Date
Apr 01, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.55
Surprise
-353.80%
Fortress Biotech, Inc.
Report Date
Mar 31, 2026 For Q4 25
Estimate
$0.11
Actual
-$0.01
Surprise
-108.91%
Tvardi Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.65
Actual
-$0.78
Surprise
-18.33%
VolitionRX Limited Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.05
Surprise
-22.35%
Soligenix, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.57
Actual
-$0.28
Surprise
+50.98%
BioAtla, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$12.24
Actual
-$8.00
Surprise
+34.64%
Sunshine Biopharma Inc.
Report Date
Apr 03, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.54
Surprise
-96.08%
FAQ
What were Fate Therapeutics, Inc.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Fate Therapeutics, Inc. reported EPS of -$0.27, beating estimates by 1.85%, and revenue of $1.37M, 1.85% above expectations.
How did the market react to Fate Therapeutics, Inc.'s Q4 2025 earnings?
The stock price moved up 5.41%, changed from $1.48 before the earnings release to $1.56 the day after.
When is Fate Therapeutics, Inc. expected to report next?
The next earning report is scheduled for May 11, 2026.
What are the forecasts for Fate Therapeutics, Inc.'s next earnings report?
Based on 13
analysts, Fate Therapeutics, Inc. is expected to report EPS of -$0.28 and revenue of $1.08M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement